FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment (Q39866881)

15 September 2017

title

FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment (English)

1 reference

chronic renal insufficiency

15 September 2017

0 references

0 references

1 reference

1 reference

Sarah Seiler

1 reference

15 September 2017

Birgit Reichart

1 reference

15 September 2017

Daniel Roth

1 reference

15 September 2017

Eric Seibert

1 reference

15 September 2017

Danilo Fliser

1 reference

15 September 2017

Gunnar H Heine

1 reference

15 September 2017

language of work or name

English

0 references

publication date

3 June 2010

1 reference

Nephrology Dialysis Transplantation

15 September 2017

published in

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

3983-3989

1 reference

Cardiovascular and noncardiovascular mortality among patients starting dialysis

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Does FGF23 toxicity influence the outcome of chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ309

21 January 2018

Identifiers

DOI

10.1093/NDT/GFQ309

1 reference

15 September 2017

1 reference